Sylvia Janetzki

Summary

Publications

  1. ncbi request reprint Evaluation of Elispot assays: influence of method and operator on variability of results
    S Janetzki
    ZellNet Consulting, Inc, 555 North Avenue, Suite 25 S, Fort Lee NJ 07024, USA
    J Immunol Methods 291:175-83. 2004
  2. ncbi request reprint Standardization and validation issues of the ELISPOT assay
    Sylvia Janetzki
    ZellNet Consulting Inc, Fort Lee, NJ, USA
    Methods Mol Biol 302:51-86. 2005
  3. pmc Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Cancer Immunol Immunother 57:303-15. 2008
  4. pmc Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells
    Sylvia Janetzki
    Cancer Vaccine Consortium of the Cancer Research Institute, New York, NY, USA
    Cancer Immunol Immunother 59:609-18. 2010
  5. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  6. pmc A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
    Sebastian Attig
    Division of Translational and Experimental Oncology, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    J Transl Med 9:108. 2011
  7. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
  8. doi request reprint The impact of harmonization on ELISPOT assay performance
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Methods Mol Biol 792:25-36. 2012
  9. ncbi request reprint A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Dig Dis Sci 52:1964-72. 2007
  10. doi request reprint A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)
    Lisa K McNeil
    Pfizer Vaccines, Pearl River, New York Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, New York
    Cytometry A 83:728-38. 2013

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Evaluation of Elispot assays: influence of method and operator on variability of results
    S Janetzki
    ZellNet Consulting, Inc, 555 North Avenue, Suite 25 S, Fort Lee NJ 07024, USA
    J Immunol Methods 291:175-83. 2004
    ..This variability was independent of operator or spot number per well. Based on this study, recommendations for standardization and validation procedures of Elispot assay performance and evaluation procedures are presented...
  2. ncbi request reprint Standardization and validation issues of the ELISPOT assay
    Sylvia Janetzki
    ZellNet Consulting Inc, Fort Lee, NJ, USA
    Methods Mol Biol 302:51-86. 2005
    ..This chapter will give the experienced scientists as well as newcomers to the field an overview over the major standardization issues for each step of the protocol. Guidelines are given on how to validate the ELISPOT performance...
  3. pmc Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Cancer Immunol Immunother 57:303-15. 2008
    ..These results provide initial harmonization guidelines to optimize Elispot assay performance to the immunotherapy community. Further optimization is in process with ongoing panels...
  4. pmc Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells
    Sylvia Janetzki
    Cancer Vaccine Consortium of the Cancer Research Institute, New York, NY, USA
    Cancer Immunol Immunother 59:609-18. 2010
    ..Recovery and viability of cells are largely unaffected by serum-free conditions even after overnight resting. Furthermore, one serum-free medium was identified that appears to enhance antigen-specific IFNgamma-secretion...
  5. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  6. pmc A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
    Sebastian Attig
    Division of Translational and Experimental Oncology, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    J Transl Med 9:108. 2011
    ..However, the impact of the introduction of a DUMP channel in multimer assays has so far not been systematically investigated across a broad variety of protocols...
  7. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  8. doi request reprint The impact of harmonization on ELISPOT assay performance
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Methods Mol Biol 792:25-36. 2012
    ..Furthermore, harmonization is discussed in the context of assay standardization and validation strategies...
  9. ncbi request reprint A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Dig Dis Sci 52:1964-72. 2007
    ..Examination of this novel approach using multiple dose levels is 1 approach to further investigate the immunogenicity and clinical utility of HSPPC-96 vaccination in this setting...
  10. doi request reprint A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)
    Lisa K McNeil
    Pfizer Vaccines, Pearl River, New York Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, New York
    Cytometry A 83:728-38. 2013
    ..2013 International Society for Advancement of Cytometry. ..
  11. pmc Improved endpoints for cancer immunotherapy trials
    Axel Hoos
    Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, NY, USA
    J Natl Cancer Inst 102:1388-97. 2010
    ..These recommendations may improve our tools for cancer immunotherapy trials and may offer a more realistic and useful model for clinical investigation...
  12. ncbi request reprint Measurement of cytokine release at the single cell level using the ELISPOT assay
    Josephine H Cox
    U S Military HIV Research Program, Henry M Jackson Foundation for the Advancement of Military Medicine, 13 Taft Court, Rockville, MD 20850, USA
    Methods 38:274-82. 2006
    ..The history, applications, validation process, and future challenges of the ELISPOT assay are discussed in this chapter...
  13. ncbi request reprint A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
    Jeffrey R Currier
    The US Military HIV Research Program, Suite 200, 13 Taft Court, Rockville, MD 20851, USA
    J Immunol Methods 260:157-72. 2002
    ..The size, shape and appearance of the spots produced using this peptide panel provided a standard for the establishment of acceptance criteria of spots for the evaluation of ELISPOT plates using an automated reader system...